PURPOSE OF REVIEW: Chronic kidney disease (CKD) is a highly prevalent condition that increases the incidence and complexity of acute coronary syndrome (ACS). The purpose of this review is to summarize current evidence, uncertainties, and opportunities in the management of patients with CKD and ACS, with a focus on revascularization. RECENT FINDINGS: Patients with CKD have been systematically under-represented or excluded from clinical trials in ACS. Available data, however, demonstrates that although patients with CKD and ACS benefit from revascularization, they are also less likely to receive recommended medical and revascularization therapies when compared to patients with normal kidney function. Despite the increased short-term risk of major morbidity and mortality, patients with CKD and ACS should be considered for an early invasive strategy while also trying to mitigate the risks of procedural related complications. Until evidence emerges from randomized clinical trials, the decision about revascularization strategy should involve multi-disciplinary collaboration, heart team consensus, and patient shared decision-making.
PURPOSE OF REVIEW: Chronic kidney disease (CKD) is a highly prevalent condition that increases the incidence and complexity of acute coronary syndrome (ACS). The purpose of this review is to summarize current evidence, uncertainties, and opportunities in the management of patients with CKD and ACS, with a focus on revascularization. RECENT FINDINGS:Patients with CKD have been systematically under-represented or excluded from clinical trials in ACS. Available data, however, demonstrates that although patients with CKD and ACS benefit from revascularization, they are also less likely to receive recommended medical and revascularization therapies when compared to patients with normal kidney function. Despite the increased short-term risk of major morbidity and mortality, patients with CKD and ACS should be considered for an early invasive strategy while also trying to mitigate the risks of procedural related complications. Until evidence emerges from randomized clinical trials, the decision about revascularization strategy should involve multi-disciplinary collaboration, heart team consensus, and patient shared decision-making.
Authors: Abduzhappar Gaipov; Miklos Z Molnar; Praveen K Potukuchi; Keiichi Sumida; Zoltan Szabo; Oguz Akbilgic; Elani Streja; Connie M Rhee; Santhosh K G Koshy; Robert B Canada; Kamyar Kalantar-Zadeh; Csaba P Kovesdy Journal: Nephrol Dial Transplant Date: 2019-11-01 Impact factor: 5.992
Authors: Robert N Foley; Anne M Murray; Shuling Li; Charles A Herzog; A Marshall McBean; Paul W Eggers; Allan J Collins Journal: J Am Soc Nephrol Date: 2004-12-08 Impact factor: 10.121
Authors: Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz Journal: N Engl J Med Date: 2005-07-21 Impact factor: 91.245
Authors: Roxana Mehran; Eve D Aymong; Eugenia Nikolsky; Zoran Lasic; Ioannis Iakovou; Martin Fahy; Gary S Mintz; Alexandra J Lansky; Jeffrey W Moses; Gregg W Stone; Martin B Leon; George Dangas Journal: J Am Coll Cardiol Date: 2004-10-06 Impact factor: 24.094
Authors: Jorge A Wong; Shaun G Goodman; Raymond T Yan; Ron Wald; Alan J Bagnall; Robert C Welsh; Graham C Wong; Jan Kornder; Kim A Eagle; Philippe Gabriel Steg; Andrew T Yan Journal: Eur Heart J Date: 2009-02-06 Impact factor: 29.983
Authors: Michel Chonchol; Jeff Whittle; Angela Desbien; Michelle B Orner; Laura A Petersen; Nancy R Kressin Journal: Am J Nephrol Date: 2007-11-29 Impact factor: 3.754